阿米三嗪—萝巴新治疗认知障碍的系统回顾  

Amitrine Bismesylate in the Treatment of Cognitive Impairment:A Systematic Review

作　　者：宋丽艳[1] 

机构地区：[1]太仓市第一人民医院神经科,江苏太仓215400

出　　处：《中国卫生产业》2011年第05Z期61-63,共3页China Health Industry

摘　　要：目的评价阿米三嗪-萝巴新治疗认知障碍的疗效和安全性。方法计算机检索Cochrane图书馆(2009年第2期),Medline(1966年至2009年),Embase(1974年至2009年)和中国生物医学文献数据库(CBM,1978年至2009年),收集所有阿米三嗪-萝巴新与安慰剂或其他药物治疗的随机对照试验,由2名研究者独立提取资料与评价质量,用RevMan软件统计分析。结果共纳入5个研究,491例患者,Meta分析显示阿米三嗪-萝巴新在总体疗效、HDS评分、MMSE评分、FAQ评分对照组比较无统计学差异,但与治疗前HDS评分、MMSE评分、FAQ评分比较均有明显改善。所有研究均未发现严重的不良反应。结论现有的临床证据来看,阿米三嗪-萝巴新治疗治疗认知障碍有效且安全性较高。但尚需更多高质量研究以增加证据的强度。Objective To evaluate efficacy and safety of amitrine bismesylate for cognitive impairment.Methods Random-- ized controlled trials（RCT） were identified from the Cochrane Library（issue 2,2009）,Medline（1966-2009）,Embase（1974-2009） and CBM（1978-2009）.RCT comparing amitrine bismesytate with ptacebe or other drug treatment were included.Two reviewers independently assessed trials quality and extracted date.The RevMan software was used for statistical analysis. Results Fifth studies involving 491 patients were included.Meta--analysis indicated that changes of total effective rate, HDS,MMSE,FAQ had no statistically significant differences between the two groups,with very significant difference in the amitrine bismesylate groups included HDS,MMSE,FAQ.No serious adverse effects were identified.Conclusion Amitrine bis-- mesylate for cognitive impairment is effective and safe from current clinical evidence.But it still needs more high quality RCT studies in order to increase the strength of the evidence.

关 键 词：阿米三嗪-萝巴新 都可喜 认知障碍 系统回顾 META分析 

分 类 号：R56[医药卫生—呼吸系统]